FRA:9IB (Sweden)
Â
Class B
€
6.29
+0.030 (+0.48%)
Jul 3
Business Description
Infant Bacterial Therapeutics AB
ISIN : SE0008015259
Share Class Description:
FRA:9IB: Class BTotal Employee Number:
6Compare
Compare
Traded in other countries / regions
IBT B.Sweden9IB.GermanyIBTBs.UKIFTBF.USA IPO Date
2025-09-19Description
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance, Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118, and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.58 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 4.1 | |||||
3-Year EPS without NRI Growth Rate | 6 | |||||
3-Year FCF Growth Rate | 11.1 | |||||
3-Year Book Growth Rate | -35.8 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 83.66 | |||||
9-Day RSI | 75.05 | |||||
14-Day RSI | 70.49 | |||||
3-1 Month Momentum % | 17.17 | |||||
6-1 Month Momentum % | 14.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.23 | |||||
Quick Ratio | 2.23 | |||||
Cash Ratio | 2.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.3 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -59.45 | |||||
ROA % | -40.35 | |||||
ROIC % | -407.19 | |||||
3-Year ROIIC % | -337.96 | |||||
ROCE % | -59.45 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 10.71 | |||||
Price-to-Tangible-Book | 12.58 | |||||
EV-to-EBIT | -11.33 | |||||
EV-to-EBITDA | -11.47 | |||||
EV-to-FCF | -12.48 | |||||
| Price-to-Net-Current-Asset-Value | 12.58 | |||||
| Price-to-Net-Cash | 13.38 | |||||
Earnings Yield (Greenblatt) % | -8.82 | |||||
FCF Yield % | -6.03 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Infant Bacterial Therapeutics AB Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.486 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 70.49 | ||
| 14-Day ATR (€) | 0.117127 | ||
| 20-Day SMA (€) | 5.79 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 3.91 - 6.46 | ||
| Shares Outstanding (Mil) | 13.47 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Infant Bacterial Therapeutics AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Infant Bacterial Therapeutics AB Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 132 days | ||
| Second quarter earnings results for 2026 | 2026-08-20 | In 47 days | ||
| General meeting for 2026 | 2026-05-07 16:00 | 4.92 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 4.91 (+0.10%) | ||
| Annual report for 2025 | 2026-03-27 | 4.42 (-2.43%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-06 | 4.31 (-1.37%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 5.30 (+0.57%) | ||
| Second quarter earnings results for 2025 | 2025-08-20 | -- | ||
| General meeting for 2025 | 2025-05-08 16:00 | -- | ||
| First quarter earnings results for 2025 | 2025-05-07 | -- |
Show
Entries
Infant Bacterial Therapeutics AB Frequently Asked Questions
What is Infant Bacterial Therapeutics AB(FRA:9IB)'s stock price today?
The current price of FRA:9IB is €6.29. The 52 week high of FRA:9IB is €6.46 and 52 week low is €3.91.
When is next earnings date of Infant Bacterial Therapeutics AB(FRA:9IB)?
The next earnings date of Infant Bacterial Therapeutics AB(FRA:9IB) is 2026-08-20 Est..
Does Infant Bacterial Therapeutics AB(FRA:9IB) pay dividends? If so, how much?
Infant Bacterial Therapeutics AB(FRA:9IB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Infant Bacterial Therapeutics AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers